logo-loader

Admedus COO encouraged by initial results from Phase II herpes vaccine trial

Published: 12:55 08 Mar 2016 GMT

Admedus Ltd's (ASX:AHZ) chief operating officer Julian Chick talks to Proactive Investors on the interim Herpes Simplex Virus Phase II clinical trial data.

The blinded trial provided data from the first 20 patients to receive at least three vaccinations in the randomised, placebo–controlled HSV-2 vaccine Phase II study.

Chick says he is “very encouraged” by the first set of results, which shows the study is “going in the right way and we are seeing what we want to see”.

Admedus Ltd 'in good shape' with minimal disruption to supply chain as it...

Admedus Ltd's (ASX:AHZ) Wayne Paterson caught up with Proactive's Andrew Scott to discuss the steps and precautions the firm's taking in the wake of the recent virus outbreak. The company's just announced the hospital discharge of the first patient following its clinical surgical aortic valve...

on 7/4/20